Latest findings on rheumatological drug therapies, including methotrexate for RA, tumor necrosis factor inhibitors for SpA
Is Shared Decision Making Possible in Rheumatology?
A rheumatologist voices skepticism that physicians, patients can arrive at mutually shared healthcare decisions
Rheumatology Advocacy Starts at Home
The ACR expands advocacy efforts to impact state legislatures, local organizations
Rheumatology Drug Updates, Trials, Safety Data
An update on baricitinib, plus safety warnings on belimumab,
eszopiclone and zoledronic acid
Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus
Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
Physicians at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco report on studies about JAK inhibitors as targeted immunomodulators and disease-modifying therapies in RA
The 2014 ACR/ARHP Annual Meeting Offers Programs for Rheumatology Clinicians, Researchers, Practice Management Professionals
Rheumatology’s premier event to be held in Boston from Nov. 14–19
Malignant Atrophic Papulosis Is Challenging to Diagnose, Treat
Patient histories, clinician reports of condition also called Köhlmeier-Degos disease underscore need for integrated, multidisciplinary care
Rheumatology Drug Updates, Trials, Safety Data
Legislative news on biosimilars, safety warning on epidural corticosteroid injections, and other drug updates rheumatologists need to know
What’s New in Inflammatory Arthritis?
Rheumatology experts at the ACR’s State-of-the-Art Clinical Symposium in Chicago discuss latest drug therapies, insights into axial spondyloarthritis and bone erosion, repair
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 40
- Next Page »